medigraphic.com
ISSN 1029-3035 (Electronic)

2023, Number 1

<< Back Next >>

Mediciego 2023; 29 (1)

Assessment of the remdesivir use for the treatment of COVID-19

Arceo-Naranjo R, González-Blanco I, Díaz-Molina M

Language: Spanish
References: 50
Page: 1-21
PDF size: 766.19 Kb.


ABSTRACT

Introduction: remdesivir is a broad-spectrum antiviral prodrug that is used for the treatment of patients hospitalized for COVID-19.
Objective: to assess the available scientific evidence on the use of remdesivir in the treatment of COVID-19.
Methods: a review of the bibliography was carried out in the databases available in Spanish and English from the Virtual Health Library, MEDLINE, Lilacs, SciELO, EBSCO and the Google Scholar search engine from 2018 to 2021. 50 articles were selected with the needed information.
Development: therapies with nucleotide/nucleoside inhibitors directed against DNA and RNA polymerase could become the core treatments of antiviral therapy. When remdesivir is converted to an active metabolite, it causes viral RNA chain termination and inhibits viral replication, which has been confirmed in pre-clinical studies. The information available from clinical trials is controversial, however, it has been shown that it improves patient recovery time and survival. Although it has shown a favorable safety profile, adverse reactions are still being reported. The five-day treatment scheme shows good efficacy and a lower rate of interruption due to adverse effects; the inhaled route appears to improve the bioavailability of remdesivir in lung tissues.
Conclusions: remdesivir is recommended for the treatment of hospitalized patients with COVID-19 and oxygen requirements, however, more research in humans is required to confirm its clinical efficacy in these patients.


REFERENCES

  1. Harapan H, Itoh N, Yufika A, Winardi W, Keam S, Te H, et al. Coronavirus disease 2019 (COVID-19): A literature review. J. Infect. Public Health [Internet]. 2020 [citado 23 Mar 2021];13(5):667-73. Disponible en: https://www.sciencedirect.com/science/article/pii/S1876034120304329

  2. Castella M, Rajnik M, Cuomo A, Dulebohn SC, Napoli RD. Features, Evaluation and Treatment of coronavirus (Covid-19). NLM. En: StatPearls [Internet]. Florida: StatPearls Publishing. 2021 [citado 20 Abr 2021]; Disponible en: https://apps.dtic.mil/sti/pdfs/AD1127230.pdf

  3. Daou F, Sleymane GA, Brado DA, Khanafer N, Tobaiqy M, Faraj AA. The History, Efficacy, and Safety of Potential Therapeutics: A Narrative Overview of the Complex Life of Covid-19. Int. J. Environ. Res. Public Health [Internet]. 2021 [citado 20 Abr 2021];18:[aprox. 16 p.]. Disponible en: https://mdpi-res.com/d_attachment/ijerph/ijerph-18-00955/article_deploy/ijerph-18-00955.pdf?version=1611325090

  4. Wu J, Liang B, Chen C, Wang H, Fang Y, Shen S, et al. SARS-CoV-2 infection induces sustained humoral immune response in convalescent patients following symptomatic COVID-19. Nat Comm [Inetrnet]. 2021 [citado 20 Abr 2021];12:[aprox. 9 p.] Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7985370/pdf/41467_2021_Article_22034.pdf

  5. Jirjees F, Saad AK, Hano ZA, Hatahet T, Obaidi HA, Bashi YD. COVID-19 Treatment Guidelines: Do They Really Reflects Best Medical Practices to Manage the Pandemic? Inf Dis Rep [Internet]. 2021 Feb 24 [citado 15 May 2021];13(2):259-84. Disponible en: https://mdpi-res.com/d_attachment/idr/idr-13-00029/article_deploy/idr-13-00029.pdf?version=1617938877

  6. Eastman RT, Roth JS, Brimacombe KR, Simeonov A, Shen M, Patnaik S, et. al. Remdesivir: A Review of its Discovery and Development Leading to Emergency Use Authorization for Treatment of Covid-19. ACS Cent Sci [Internet]. 2020 [citado 13 Abr 2021];6(5):672-83. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7202249/pdf/oc0c00489.pdf

  7. Wang C, Wang Z, Wang G, Lau JAY, Zang K, Li W. COVID-19 in early 2021: current status and looking forward. Signal Transduct Target Ther [Internet]. 2021 [citado 13 Abr 2021];6:[aprox. 14 p.]. Disponible es: https://www.nature.com/articles/s41392-021-00527-1.pdf

  8. Díaz-Catrillón F, Toro-Montoya AI. SARS-CoV-2/Covid-19: el virus la enfermedad y la pandemia. EMC [Internet]. 2020 [citado 13 Abr 2021];24(3):183-205. Disponible en: https://docs.bvsalud.org/biblioref/2020/05/1096519/covid-19.pdf

  9. National Institutes of Health. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. NIH [Internet]. [citado 13 Abr 2021]. Disponible en: https://www.covid19treatmentguidelines.nih.gov/

  10. Sun D. Remdesivir for treatment of Covid-19: Combination of Pulmonary and IV Administration May Offer Aditional Benefits. AAPS J [Internet]. 2020 [citado 13 Abr 2021];22(4):[aprox. 6 p.]. Disponible es: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7250281/pdf/12248_2020_Article_459.pdf

  11. Mehta N, Mazer-Amirshahi M, Alkindi N, Pourmand A. Pharmacotherapy in Covid-19; A narrative review for emergency providers. Am J Emerg Med [Internet]. 2020 [citado 13 Abr 2021];38(7):1488-93. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7158837/pdf/main.pdf

  12. Gómez JT, Dieguez RG, Pérez MA. Alternativas terapéuticas para el manejo de la Covid-19. Ciencias Clínicas y Patológicas. Rev haban cienc méd [Internet]. 2020 [citado 13 Abr 2021];19(Supl. 1):[aprox. 15 p.]. Disponible en: http://scielo.sld.cu/pdf/rhcm/v19s1/1729-519X-rhcm-19-s1-e3328.pdf

  13. Lu G, Zhang X, Zheng W, Sun J, Hua Lan, Xu L, et al. Development of a Simple In Vitro Assay To Identify and Evaluate Nucleotide Analogs against SARS-CoV-2 RNA Dependent RNA Polymerase. Antimicrob Agents Chemother [Internet]. 2020 [citado 13 Abr 2021];65(1):e1508-20. Disponible en: https://journals.asm.org/doi/pdf/10.1128/AAC.01508-20

  14. Kumar I. A review on pharmacokinetics, pharmacodynamics and clinical aspects of remdesivir and favipiravir for the treatment of coronavirus diseases. Journal of Drug Delivery and Therapeutics [Internet]. 2021 [citado 13 Abr 2021];11(1):121-29. Disponible en: https://www.researchgate.net/profile/Inder-Kumar-2/publication/348554319_A_review_on_pharmacokinetics_pharmacodynamics_and_clinical_aspects_of_remdesivir_and_favipiravir_for_the_treatment_of_coronavirus_disease/links/6003b07692851c13fe17f5c4/A-review-on-pharmacokinetics-pharmacodynamics-and-clinical-aspects-of-remdesivir-and-favipiravir-for-the-treatment-of-coronavirus-disease.pdf

  15. Byléhn F, Menéndez CA, Pérez-Lemus GR, Alvarado W, De Pablo JJ. Modeling the Binding Mechanism of Remdesivir, Favipiravir, and Ribavirin to SARS-CoV-2 RNA-Dependent RNA Polymerase. ACS Cent Sci [Internet]. 2017 [citado 13 Abr 2021];7(1):164-74. Disponible en: https://pubs.acs.org/doi/pdf/10.1021/acscentsci.0c01242

  16. Rezagholizadeh A, Khiali S, SarbaKhsh P, Entezari–Maleki T. Remdesivir for Treatment of Covid-19: an updated systematic review and meta-analysis. Eur J Pharmacol [Internet]. 2021 [citado 13 Abr 2021];897:[aprox. 8 p.]. Disponible en: https://www.sciencedirect.com/science/article/pii/S0014299921000790

  17. Davis M, Osborne V, Lane S, Roy D, Dhanda S, Evans A, et al. Remdesivir in Treatment of Covid-19: A Systematic Benefic-Risk Assessment. Drug Saf [Internet]. 2020 [citado 13 Abr 2021];43(7):645-56. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7255634/pdf/40264_2020_Article_952.pdf

  18. Aleissa MM, Silverman EA, Paredes AL, Nutt CT, Richterman A, Marty F. New Perpective of Antimicrobial Agents: Remdesivir Treatment for Covid-19. Antimicrob Agents Chemother [Internet]. 2020 [citado 13 Abr 2021];65(1):[aprox. 18 p.]. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7927874/pdf/AAC.01814-20.pdf

  19. Dal-Ré R, Banzi R, Georgin-Lavialle S, Porcher R, Sofat R, Zeitlinger M, et al. Remdesivir for Covid-19 in Europe: will it provide value for money? Comment. Lancet [Internet]. 2021 [citado 13 Abr 2021];9(2):127-28. Disponible en: https://www.sciencedirect.com/sdfe/reader/pii/S2213260020305683/pdf

  20. Xu Y, Barauskas O, Kim C, Babusis D, Murakami E, Kornyeyev D, et al. Off-Target In Vitro Profiling Demostrates that Remdesivir Is a Highly Selective Antiviral Agent. ASM AAC [Internet]. 2021 [citado 13 Abr 2021];65(2):[aprox. 14 p.]. Disponible en: https://journals.asm.org/doi/pdf/10.1128/aac.02237-20

  21. Bhimraj A, Morgan RL, Shumarker AH, Lavergne V, Baden L, Cheg VCC, et al. Infectious Diseases Society of American Guideline on the Treatment and Management of Patients with Covid-19. IDSA [Internet]. 2020 [citado 13 Abr 2021]; Version 4.2.1. Disponible en: https://www.idsociety.org/globalassets/idsa/practice-guidelines/covid-19/treatment/idsa-covid-19-gl-tx-and-mgmt-v9.0.0.pdf

  22. Frediansyanh A, Nainu F, Dhama K, Mudatsir M, Harapan H. Remdesivir and its antiviral activity against COVID-19: A Systematic Review. Clin. Epidemiology Glob. Health. [Internet]. 2020 [citado 13 Abr 2021];9:123-27. Disponible en: https://www.sciencedirect.com/science/article/pii/S2213398420301810

  23. Humeniuk R, Mathias A, Kirby BJ, Lutz JD, Cao H, Osinusi A, et al. Pharmacokinetic, Pharmacodynamic, and Drugs Interaction Profile of Remdesivir, a SARS-CoV-2 Replication Inhibitor. Clin Pharmacokinet [Internet]. 2021 [citado 13 Abr 2021];60:569-83. Disponible en: https://link.springer.com/content/pdf/10.1007/s40262-021-00984-5.pdf

  24. Sherwat A, Murray J, Birnkrant D, Farley J. Combined Cross-Discipline Team Leader, Division Director and ODE Director Summery Review. Center for Drugs Evaluation and Research. Application Number: 214787rig1s000. Summary Review. Gialead Sciences Inc [Internet]. 21 Oct 2020 [citado 13 Abr 2021]; NDA 214787. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/214787Orig1s000Sumr.pdf

  25. Jaime-Lin HX, Cho S, Meyyur-Aravamudan V, Yu-Sanda H, Palraj R, Molton JS, et al. Remdesivir in Coronavirus Disease 2019 (COVID-19) treatment: a review of evidence. Infection [Internet]. 2020 [citado 13 Abr 2021];49(3):201-10. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7778417/pdf/15010_2020_Article_1557.pdf

  26. Killegeros M, Tashima KT, Mylona EK, Rybal N, Flanigan TP, Farmakiotis D, et al. Remdesir Use Compared With Supportive Care in Hospitalized Patients With Severe COVID-19: A single Single-Center Experience. Open Forum Infect Dis [Internet]. 2020 [citado 13 Abr 2021];7(10):[aprox. 8 p.]. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7454852/pdf/ofaa319.pdf

  27. Wang Y, Zhang D, Du G, Du R, Zhao J, Jin Y, et al. Remdesivir in adults with severe Covid-19: a randomised, double blind, placebo-controlled, multicentre trial. Lancet [Internet] 2020 [citado 13 Abr 2021];395:1569-78. Disponible en: http://klinikfarmakoloji.com/sites/default/files/2020-08/remdesivir-wang.pdf

  28. Al-Abdouh A, Bizanti A, Barbarawi M, Jadri A, Kumar A, Fashanu OE, et al. Remdesivir for treatment of Covid-19: A systematic review and meta-analysis of randomized controlled trials. Contemp Clin Trials [Internet]. 2021 [citado 13 Abr 2021];101. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7789823/pdf/main.pdf

  29. Kelleni M. Tocilizumab, Remdesivir, Favipiravir, and Dexamethasone Repurposed for Covid-19: a Comprenhensive Clinical and Pharmacovigilant Reassessment. SN Compr Clin Med [Internet]. 2021 [citado 13 Abr 2021];3(4):919-23. Disponible en: https://link.springer.com/content/pdf/10.1007/s42399-021-00824-4.pdf?pdf=button%20sticky

  30. Beigel JH, Tomashek KM, Dodd LE, Metha AK, Zingman BS, Kalil AC, et al. Remdesivir for Treatment of Covid-19- Final Report. N Engl J Med [Internet]. 2020 [citado 13 Abr 2021];383(19):1813-26. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7262788/pdf/NEJMoa2007764.pdf

  31. Musa A, Pendi K, Hashemi A, Warbasse E, Kouyoumjian S, Yousif J, et al. Remdesivir for the Treatment of Covid-19: A Systematic Review of the Literature. West J Emerg Med [Internet]. 2020 [citado 13 Abr 2021];21(4):737-41. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7390571/pdf/wjem-21-737.pdf

  32. Spinner CD, Gottlieb RL, Criner GJ, Arribas LJR, Cattelan AM, Viladomiu SA, et al. Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderates Covid-19: a Ramdomized Clinical Trial. JAMA [Internet]. 2020 [citado 13 Abr 2021];324(11):1048-57. Disponible en: https://jamanetwork.com/journals/jama/articlepdf/2769871/jama_spinner_2020_oi_200097_1600070022.50408.pdf

  33. Hu WJ, Chang L, Yang Y, Wang X, Xie YC, Shen JS, et al. Pharmacokinetics and tissues Distribuition of remdesivir and its metabolites nucleotide monophosphate, nucleotide triphosphate, and nucleoside in mice. Acta Pharmacol. Sin [Internet]. 2020 [citado 13 Abr 2021];42(7):[aprox. 6 p.]. Disponible en: https://www.researchgate.net/profile/Bo-Tan-14/publication/345365827_Pharmacokinetics_and_tissue_distribution_of_remdesivir_and_its_metabolites_nucleotide_monophosphate_nucleotide_triphosphate_and_nucleoside_in_mice/links/5fd897ca299bf140880f8ea9/Pharmacokinetics-and-tissue-distribution-of-remdesivir-and-its-metabolites-nucleotide-monophosphate-nucleotide-triphosphate-and-nucleoside-in-mice.pdf?origin=publication_detail

  34. Patrick-Lê M, Hingrat-Le Q, Jaquet P, Wicky PH, Bunel V, Massias L, et al. Removal of Remdesivir’s Metabolite GS-441524 by Hemodialysis in Double Lung Transplant Recipient with Covid-19. ASM J [Internet]. 2020 [citado 13 Abr 2021];64(11):e1521-20. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7577145/pdf/AAC.01521-20.pdf

  35. Sahakijpijarn S, Moon C, Warnken ZN, Maier EY, DeVore JE, Christensen DJ, et al. In vivo pharmacokinetic study of remdesivir dry powder for inhalation in hamsters. Int. J. Pharm [Internet]. 2021 [citado 13 Abr 2021];3[aprox. 7 p.]. Disponible en: https://www.sciencedirect.com/science/article/pii/S2590156721000025

  36. Goldman JD, Lye DC, Hui DS, Marks KS, Bruno R, Montejano R, et al. Remdesivir for 5 or 10 Days in Patients with Severe Covid-19. N Engl J Med [Internet]. 2020 [citado 13 Abr 2021];383(19):1827-37. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7377062/pdf/NEJMoa2015301.pdf

  37. Nies AT, König J, Hofmann U, Kölz C, Fromm MF, Schwab M. Interaction of Remdesivir with Clinically Relevant Hepatic Drugs Uptake Transporter. Pharmaceutics [Internet]. 2021 [citado 13 Abr 2021];13(3):[aprox 8 p.]. Disponible en: https://mdpi-res.com/d_attachment/pharmaceutics/pharmaceutics-13-00369/article_deploy/pharmaceutics-13-00369-v2.pdf?version=1615451326

  38. Peyko V, Ledd H, Cutrona A. The Safety Administration of Remdesivir in a Patient with Acute Kidney Injury Requiring Hemodialysis. Case Rep Infect Dis [Internet]. 2020 [citado 13 Abr 2021]:[aprox. 5 p.]. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7771254/pdf/CRIID2020-8811798.pdf

  39. Thakare S, Gandhi C, Modi T, Bose S, Deb S, Saxena N, et al. Safety of Remdesivir in Patients With Acute Kidney Injury or CKD. Kidney Int Rep [Internet]. 2020 [citado 13 Abr 2021];6(1):206-10. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7547837/pdf/main.pdf

  40. Sörgel F, Malin JJ, Hagmann H, Kinzing M, Bilal M, Eichenauer DA, et al. Pharmacokinetics of remdesivir in a Covid-19 patient with end-stage renal disease on intermittent haemodialysis. J Antimicrob Chemother [Internet]. 2020 [citado 13 Abr 2021];76(3):825-27. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7799013/pdf/dkaa500.pdf

  41. Ackley TW, McManus D, Topal JE, Cicali B, Shah S. A Valid Warning or Clinical Lore: an Evaluation of Safety Outcomes of Remdesivir in Patients with Impaired Renal Function from a Multicenter Matched Cohort. Antimicrob. Agents Chemother [Internet]. 2021 [citado 1 May 2021];65(2):[aprox. 9 p.]. Disponible : https://journals.asm.org/doi/epub/10.1128/AAC.02290-20

  42. Adapa S, Chenna A, Balla M, Prasad GM, Koduri NM, Doggubati SR, et al. Covid-19 Pandemia Causing Acute Kidney Injury and Impacto in Patients With Chronic Kidney Diseases and Renal Transplantation. J Clin Med Res [Internet]. 2020 [citado 1 May 2021];12(6):352-61. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7295554/pdf/jocmr-12-352.pdf

  43. Xu Z, Tang Y, Huang Q, Fu Sha, Li X, Lin B, et al. Systematic review and subgroup analysis of the incidence of acute kidney injury (AKI) in patients with Covid-19. BMC Nephrol [Internet]. 2021 [citado 1 May 2021];22(1):[aprox. 10 p.]. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7863041/pdf/12882_2021_Article_2244.pdf

  44. Kalil AC, Patterson ACK, Mehta AK, Tomashek KM, Ghazaryan WV, Marconi VC, et al. Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19. N Engl J Med [Internet]. 2021 [citado 1 May 2021];384(9):795-807. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7745180/pdf/NEJMoa2031994.pdf

  45. Ghosh CK, Hasan SMA, Dey S. Remdesivir Induced Liver Injury and Severe Covid-19 Infection. Am. J. Med [Internet]. 2020 [citado 1 May 2021];8(6):285-88. Disponible en: https://article.sciencepublishinggroup.com/pdf/10.11648.j.ajim.20200806.18.pdf

  46. Téllez L, Martín-Mateos RM. Actualización en Covid-19 y enfermedades hepáticas. Gastroenterol Hepatol [Internet]. 2020 [citado 1 May 2021];43(8):472-80. Disponible en: https://www.elsevier.es/es-revista-gastroenterologia-hepatologia-14-pdf-S0210570520302417

  47. Nardo AD, Gleixner MS, Bakail M, Dixon ED, Lax SF, Trauner M. Phatophysiological Mechanisms of Liver Injury in Covid-19. Liver Int [Internet]. 2020 [citado 1 May 2021];41(1):[aprox 13 p.]. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7753756/pdf/LIV-9999-na.pdf

  48. Vitiello A, Porta RL, D´Aiuto V, Ferrara F. The risks of liver injury in Covid-19 patients and pharmacological management to reduce or prevent the damage induced. Egypt Liver J [Internet]. 2021 [citado 1 May 2021];11(1):[aprox. 11 p.]. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7838235/pdf/43066_2021_Article_82.pdf

  49. Jorgensen SCJ, Kebriaei R, Dresser LD. Remdesivir: Review of Pharmacology, Pre-Clinical Data and Emerging Clinical Experience for Covid-19. Pharmacotherapy [Internet]. 2020 [citado 1 May 2021];40(7):659-71. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7283864/pdf/PHAR-9999-na.pdf

  50. MohammadReza-Hashemian S, Farhadi T, Akbar AV. A Review on Remdesivir: A Possible Promising Agent for the Treatment of Covid-19. Drug Des Devel Ther [Internet]. 2020 [citado 1 May 2021];2020(14):3215-22. Disponible en: https://www.tandfonline.com/doi/full/10.2147/DDDT.S261154




2020     |     www.medigraphic.com